



Practitioner's Docket No. 701039-047875 C

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Klagsbrun et al.
Application No.: 09/579,420 Group No.: 1642
Filed: May 25, 2000 Examiner: G. Nickol
For: PEPTIDE ANTAGONISTS OF VASCULAR ENDOTHELIAL
GROWTH FACTOR

CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. § 1.8(a) and 1.10)

I hereby certify that this correspondence:

1. Transmittal Form (1 pg.);
2. Response After Final Under C.F.R. §1.116 (1 pg.);
3. Return Receipt Postcard;

is on the date shown below being:


MAILING

X deposited with the United States Postal Service
and with sufficient postage as first class mail in an
envelope addressed to MAIL STOP AF,
Commissioner for Patents, P.O. Box 1450,
Alexandria, VA 22313-1450

Date: July 25, 2003

FACSIMILE

transmitted by facsimile to the Patent
Trademark Office.


Signature

Nicole M. Gignac
(type or print name of person certifying)



PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Application Number	09/579,420
Filing Date	May 25, 2000
First Named Inventor	Michael Klagsbrun
Art Unit	1642
Examiner Name	G. Nickol
Attorney Docket Number	701039-047875-C

Total Number of Pages in This Submission

RECEIVED

JUL 29 2003

TECH CENTER 1600/2900

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input checked="" type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	Certificate of Mailing; Return Receipt Postcard.
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	Remarks	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	The Commissioner is authorized to charge any fee deficiencies associated with this filing to the NIXON PEABODY LLP Deposit Account No. 50-0850.	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	David S. Resnick (Reg. No. 34,235) NIXON PEABODY LLP, 101 Federal Street, Boston, MA 02110
Signature	
Date	8/25/03

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. Washington, DC 20231 on this date:

Typed or printed name	Nicole M. Gignac		
Signature		Date	07/25/2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Practitioner's Docket No. 701039-047875-C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Klagsbrun et al.
Application No.: 09/579,420 Group No.: 1642
Filed: May 25, 2000 Examiner: G. Nickol
For: PEPTIDE ANTAGONISTS OF VASCULAR ENDOTHELIAL
GROWTH FACTOR

RECEIVED
PATENT
JUL 29 2003
TECH CENTER 1600/2900

CERTIFICATE OF MAILING (37 C.F.R. SECTION 1.8(a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to MAIL STOP AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Date 7/25/2003

Nicole M. Gignac

(type or print name of person mailing paper)

Nicole M. Gignac
Signature of person mailing paper

18ms
KO
9/4/03

RESPONSE UNDER
37 C.F.R. 1.116
EXAMINING GROUP
1642

MAIL STOP AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO OFFICE ACTION UNDER 37 C.F.R. 1.116

SIR:

With reference to the Office Action mailed May 6, 2003, Applicants respond as follows.

Remarks/Arguments begin on page 2 of this paper.

DO NOT
enter
GW 09/25/03